Cogent Biosciences, Inc. Additional Paid in Capital, Common Stock
Cogent Biosciences, Inc. (COGT) had Additional Paid in Capital, Common Stock of $1.85 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-10
- 2026-06-30: Additional Paid in Capital, Common Stock $1.85B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.83B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.73B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.28B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.85B 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $1.83B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.73B 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $1.28B 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $1.05B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.04B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.00B 10-K · filed 2026-02-17 | |
| 2024-09-30 | $994.61M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $980.11M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $862.10M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $801.06M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $792.21M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $780.01M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $610.97M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $601.15M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $595.80M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $584.45M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $411.02M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $399.71M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $357.86M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $354.34M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $342.47M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $322.45M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $165.18M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $156.59M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $155.66M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $155.65M 10-K · filed 2021-03-16 | $155.62M 10-K · filed 2020-03-26 |
| 2019-09-30 | $154.78M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $153.99M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $153.01M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $152.28M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $150.98M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $149.94M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $2.99M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $2.50M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |